266 related articles for article (PubMed ID: 35196614)
41. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4.
Kang HJ; Kim JH; Joo I; Han JK
Abdom Radiol (NY); 2020 Jan; 45(1):55-63. PubMed ID: 31332503
[TBL] [Abstract][Full Text] [Related]
42. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival?
Yang J; Huang JY; Chen X; Ling WW; Luo Y; Shi YJ; Liu JB; Lu Q; Lyshchik A
Eur Radiol; 2021 Aug; 31(8):6397-6405. PubMed ID: 33492470
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma.
Shahbazian H; Birnbaum J; Burns PJ; Shabanan SH; Kanmaniraja D; Reinus J; Kamel I; Sirlin CB; Chernyak V
Abdom Radiol (NY); 2023 Dec; 48(12):3696-3702. PubMed ID: 37725110
[TBL] [Abstract][Full Text] [Related]
44. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
46. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI.
Choi SH; Jeon SK; Lee SS; Lee JM; Hur BY; Kang HJ; Kim H; Park Y
Eur Radiol; 2021 Dec; 31(12):9479-9488. PubMed ID: 34037829
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of contrast-enhanced ultrasound LI-RADS version 2017: application on 271 liver nodules in individuals with non-alcoholic steatohepatitis.
Huang Z; Zhou P; Li S; Li K
Eur Radiol; 2022 Oct; 32(10):7146-7154. PubMed ID: 35639147
[TBL] [Abstract][Full Text] [Related]
48. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
[TBL] [Abstract][Full Text] [Related]
49. Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study.
Makoyeva A; Kim TK; Jang HJ; Medellin A; Wilson SR
Radiol Imaging Cancer; 2020 Mar; 2(2):e190014. PubMed ID: 33778701
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
52. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI.
Wilson SR; Lyshchik A; Piscaglia F; Cosgrove D; Jang HJ; Sirlin C; Dietrich CF; Kim TK; Willmann JK; Kono Y
Abdom Radiol (NY); 2018 Jan; 43(1):127-142. PubMed ID: 28819825
[TBL] [Abstract][Full Text] [Related]
53. Inter-reader agreement of CEUS LI-RADS among radiologists with different levels of experience.
Li W; Li L; Zhuang BW; Ruan SM; Hu HT; Huang Y; Lin MX; Xie XY; Kuang M; Lu MD; Chen LD; Wang W
Eur Radiol; 2021 Sep; 31(9):6758-6767. PubMed ID: 33675388
[TBL] [Abstract][Full Text] [Related]
54. Role of Contrast-Enhanced Ultrasonography in Hepatocellular Carcinoma by Using LI-RADS and Ancillary Features: A Single Tertiary Centre Experience.
Ciocalteu A; Iordache S; Cazacu SM; Urhut CM; Sandulescu SM; Ciurea AM; Saftoiu A; Sandulescu LD
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943474
[TBL] [Abstract][Full Text] [Related]
55. Compared with CT/MRI LI-RADS, whether CEUS LI-RADS is worth popularizing in diagnosis of hepatocellular carcinoma?-a direct head-to-head meta-analysis.
Wang H; Cao J; Fan H; Huang J; Zhang H; Ling W
Quant Imaging Med Surg; 2023 Aug; 13(8):4919-4932. PubMed ID: 37581040
[TBL] [Abstract][Full Text] [Related]
56. Sonazoid-enhanced ultrasonography: comparison with CT/MRI Liver Imaging Reporting and Data System in patients with suspected hepatocellular carcinoma.
Hwang JA; Jeong WK; Min JH; Kim YY; Heo NH; Lim HK
Ultrasonography; 2021 Oct; 40(4):486-498. PubMed ID: 33745266
[TBL] [Abstract][Full Text] [Related]
57. CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Lee S; Kim YY; Shin J; Hwang SH; Roh YH; Chung YE; Choi JY
J Am Coll Radiol; 2020 Oct; 17(10):1199-1206. PubMed ID: 32640250
[TBL] [Abstract][Full Text] [Related]
58. Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.
Guo D; Wan W; Bai X; Wen R; Peng J; Lin P; Liao W; Huang W; Liu D; Peng Y; Kang T; Yang H; He Y
Abdom Radiol (NY); 2024 May; 49(5):1432-1443. PubMed ID: 38584190
[TBL] [Abstract][Full Text] [Related]
59. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
[TBL] [Abstract][Full Text] [Related]
60. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters.
Centonze L; Di Sandro S; Lauterio A; De Carlis R; Sgrazzutti C; Ciulli C; Vella I; Vicentin I; Incarbone N; Bagnardi V; Vanzulli A; De Carlis L
Transpl Int; 2021 Sep; 34(9):1712-1721. PubMed ID: 34448275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
